TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Teva Pharmaceutical Industries Ltd quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax history and growth rate from Q1 2010 to Q3 2024.
  • Teva Pharmaceutical Industries Ltd Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending September 30, 2024 was -$2.77B, a 4.85% increase year-over-year.
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 -$2.77B +$141M +4.85% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$2.88B -$204M -7.62% Jun 30, 2024 10-Q 2024-07-31
Q1 2024 -$2.78B -$74M -2.74% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$2.7B +$141M +4.97% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 -$2.91B +$243M +7.71% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$2.68B +$124M +4.43% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 -$2.7B -$14M -0.52% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 -$2.84B -$155M -5.78% Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$3.15B -$533M -20.3% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 -$2.8B -$355M -14.5% Jun 30, 2022 10-Q 2022-07-27
Q1 2022 -$2.69B -$153M -6.04% Mar 31, 2022 10-Q 2022-05-03
Q4 2021 -$2.68B -$284M -11.8% Dec 31, 2021 10-K 2023-02-10
Q3 2021 -$2.62B +$23M +0.87% Sep 30, 2021 10-Q 2021-10-27
Q2 2021 -$2.45B +$257M +9.51% Jun 30, 2021 10-Q 2021-07-28
Q1 2021 -$2.53B +$318M +11.2% Mar 31, 2021 10-Q 2021-04-28
Q4 2020 -$2.4B -$87M -3.76% Dec 31, 2020 10-K 2022-02-09
Q3 2020 -$2.64B -$278M -11.8% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 -$2.7B -$391M -16.9% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 -$2.85B -$493M -20.9% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 -$2.31B +$147M +5.98% Dec 31, 2019 10-K 2021-02-10
Q3 2019 -$2.37B -$30M -1.29% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 -$2.31B -$23M -1.01% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 -$2.36B -$624M -36% Mar 31, 2019 10-Q 2019-05-02
Q4 2018 -$2.46B -$606M -32.7% Dec 31, 2018 10-K 2020-02-21
Q3 2018 -$2.34B -$138M -6.28% Sep 30, 2018 10-Q 2018-11-01
Q2 2018 -$2.29B +$111M +4.63% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 -$1.74B +$979M +36.1% Mar 31, 2018 10-Q 2018-05-03
Q4 2017 -$1.85B +$1.31B +41.3% Dec 31, 2017 10-K 2019-02-19
Q3 2017 -$2.2B +$509M +18.8% Sep 30, 2017 6-K 2017-11-02
Q2 2017 -$2.4B +$144M +5.66% Jun 30, 2017 6-K 2017-08-03
Q1 2017 -$2.71B -$478M -21.4% Mar 31, 2017 6-K 2017-05-11
Q4 2016 -$3.16B -$1.2B -61.6% Dec 31, 2016 10-K 2018-02-12
Q3 2016 -$2.71B -$565M -26.4% Sep 30, 2016 6-K 2017-11-02
Q2 2016 -$2.54B -$651M -34.4% Jun 30, 2016 6-K 2017-08-03
Q1 2016 -$2.24B -$314M -16.3% Mar 31, 2016 6-K 2016-05-09
Q4 2015 -$1.96B -$612M -45.6% Dec 31, 2015 10-K 2018-02-12
Q3 2015 -$2.14B -$1.31B -156% Sep 30, 2015 6-K 2015-10-29
Q2 2015 -$1.89B -$1.64B -639% Jun 30, 2015 6-K 2015-07-30
Q1 2015 -$1.92B -$1.68B -678% Mar 31, 2015 6-K 2015-04-30
Q4 2014 -$1.34B -$1.25B -1376% Dec 31, 2014 10-K 2018-02-12
Q3 2014 -$836M -$679M -432% Sep 30, 2014 6-K 2014-10-30
Q2 2014 -$256M +$198M +43.6% Jun 30, 2014 6-K 2014-07-31
Q1 2014 -$247M +$4M +1.59% Mar 31, 2014 6-K 2014-05-02
Q4 2013 -$91M -$74M -435% Dec 31, 2013 20-F 2017-02-15
Q3 2013 -$157M +$76M +32.6% Sep 30, 2013 6-K 2013-10-31
Q2 2013 -$454M +$230M +33.6% Jun 30, 2013 6-K 2013-08-01
Q1 2013 -$251M -$393M -277% Mar 31, 2013 6-K 2013-05-02
Q4 2012 -$17M +$572M +97.1% Dec 31, 2012 20-F 2015-02-09
Q3 2012 -$233M -$519M -181% Sep 30, 2012 6-K 2012-11-01
Q2 2012 -$684M -$2.24B -144% Jun 30, 2012 6-K 2012-08-02
Q1 2012 $142M -$1.12B -88.7% Mar 31, 2012 6-K 2012-05-09
Q4 2011 -$589M -$939M -268% Dec 31, 2011 20-F 2014-02-10
Q3 2011 $286M -$353M -55.2% Sep 30, 2011 6-K 2011-11-02
Q2 2011 $1.56B +$2.34B Jun 30, 2011 6-K 2011-07-28
Q1 2011 $1.26B +$982M +351% Mar 31, 2011 6-K 2011-05-11
Q4 2010 $350M Dec 31, 2010 20-F 2013-02-12
Q3 2010 $639M Sep 30, 2010 6-K 2010-11-02
Q2 2010 -$779M Jun 30, 2010 6-K 2010-07-27
Q1 2010 $280M Mar 31, 2010 6-K 2010-05-04
* An asterisk sign (*) next to the value indicates that the value is likely invalid.